Panelists discuss how the needs of older patients with spinal muscular atrophy (SMA) differ from infants, focusing on independence, education, career goals, fatigue management, and quality of life ...

Access to timely treatment for spinal muscular atrophy (SMA) remains a challenge, with barriers including delays in diagnosis, frequent treatment needs, and insurance coverage gaps, which impact ...

Novartis is telling people living with spinal muscular atrophy (SMA), a rare neuromuscular disease, to “SMAsh” their limits in a recently-launched campaign. SMA is a rare genetic neuromuscular disease ...

Affordable Risdiplam is now within reach for Spinal Muscular Atrophy (SMA) patients in India, thanks to a Delhi High Court ...

Evrysdi is the only non-invasive disease-modifying SMA treatment and is approved in over 100 countries Evrysdi tablet can be stored at room temperature and offers the same demonstrated efficacy and ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on advancing innovative treatments for spinal muscular atrophy (SMA), cardiometabolic ...

August marks Spinal Muscular Atrophy month. The genetic neuromuscular disease causes loss of motor neurons, which can affect muscle function. One Dallas teen is changing the perception of those who ...

Delhi High Court dismisses Roche's appeal, allowing Natco Pharma to launch generic version of rare diseases drug.